Large Doses of Vitamin D Fail to Increase 25-Hydroxyvitamin D Levels or to Alter Cardiovascular Risk Factors in Obese Adolescents: A Pilot Study
| Autor: | Darrell M. Wilson, Laura K. Bachrach, Sejal Shah |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Pediatric Obesity Adolescent Pilot Projects Overweight vitamin D deficiency Proinflammatory cytokine Body Mass Index Insulin resistance Double-Blind Method Risk Factors Internal medicine medicine Vitamin D and neurology Humans Vitamin D Inflammation Adiponectin business.industry Public Health Environmental and Occupational Health Vitamins medicine.disease Lipids Psychiatry and Mental health Ergocalciferol Endocrinology Cardiovascular Diseases Pediatrics Perinatology and Child Health Ergocalciferols Female medicine.symptom business Body mass index Biomarkers medicine.drug |
| Zdroj: | The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 57(1) |
| ISSN: | 1879-1972 |
| Popis: | Purpose Vitamin D deficiency and cardiometabolic risk factors are common in obese adolescents. Observational studies demonstrate an inverse relationship among serum 25-hydroxyvitamin D (25OHD) and obesity, insulin resistance, and inflammatory cytokines. This pilot study explores if vitamin D supplementation could reduce serum concentrations of inflammatory cytokines (interleukin [IL] 6, IL-10, tumor necrosis factor α), adiponectin, lipids, hemoglobin A1C, and high-sensitivity C-reactive protein (hs-CRP). A secondary aim was to determine the associations between baseline serum 25OHD concentrations and body mass index (BMI), hs-CRP, inflammatory cytokines, and lipids. Methods Overweight and obese adolescents enrolled in this 24-week, randomized, double-blind study were given 150,000 IU ergocalciferol or placebo at baseline and 12 weeks. Outcome measurements included serum 25OHD, inflammatory cytokines, adiponectin, hs-CRP, lipids, hemoglobin A1C, and BMI at baseline, 12, and 24 weeks. Results Of 40 participants, 31 (78%) completed the study. Mean ± standard error 25OHD levels were similar in vitamin D and placebo groups at baseline (19.6 ± 5.3 vs. 25.8 ± 10.8 ng/mL) and 24 weeks (20.1 ± 3.4 vs. 24.6 ± 8.4 ng/mL). Inflammatory and cardiovascular markers were not significantly different between groups at 24 weeks. Serum 25OHD at baseline was associated with BMI ( r = −.44 [95% confidence interval, −.66 to −.15]) but not with other outcome measures. Conclusions Supplementation with vitamin D at 150,000 IU every 3 months failed to increase serum 25OHD or alter inflammatory markers and lipids in overweight and obese youth. Further studies are needed to establish the dose of vitamin D required to increase 25OHD and determine potential effects on metabolic risk factors in obese teens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect